Leptoprol

Leuprorelin, the active ingredient in Leptoprol, is a GnRH agonist presented as a sterile solution for subcutaneous use. It is employed in hormone therapy to manage prostate cancer, breast cancer, endometriosis, uterine fibroids and precocious puberty by suppressing sex steroid production.

GNH USA supplies Leptoprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets with robust cold‑chain logistics and dedicated technical support for all product batches.

Leuprorelin is a GnRH agonist used in hormone‑dependent disease pathways to achieve medical castration or hormonal suppression.

- Prostate cancer: reduces testosterone levels to slow tumor growth. - Breast cancer (hormone‑responsive): lowers estrogen production to inhibit tumor progression. - Endometriosis: suppresses estrogen to alleviate pelvic pain and lesion growth. - Uterine fibroids: decreases estrogen stimulation, leading to fibroid shrinkage. - Precocious puberty: blocks premature gonadotropin release to delay sexual maturation.

Leuprorelin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Injection site reactions: redness, pain or swelling at the subcutaneous site. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Decreased libido: reduced sexual desire. - Mood changes: irritability or depressive symptoms.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, thromboembolic phenomena. - Severe allergic reaction: anaphylaxis, angioedema. - Bone mineral density loss: increased risk of osteoporosis with long‑term use. - Pituitary apoplexy: rare hemorrhage within the pituitary gland.

Leuprorelin therapy requires careful monitoring and patient education.

- Hormone level monitoring: assess testosterone or estradiol periodically to confirm suppression. - Bone health assessment: evaluate bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular risk screening: monitor blood pressure, lipid profile, and signs of thrombosis. - Contraindication in pregnancy: avoid use in pregnant women due to fetal risk. - Use in pediatric patients: only under specialist supervision for precocious puberty. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other agents that influence hormonal balance or drug metabolism.

Major Interactions (Avoid): - Estrogen replacement therapy: may counteract the intended hormonal suppression. - High‑dose corticosteroids: can interfere with GnRH receptor down‑regulation.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampicin): may reduce efficacy of concomitant hormonal agents. - Anticoagulants: monitor coagulation parameters as hormonal changes can affect clotting risk. - Antidepressants (SSRIs): may exacerbate mood‑related side effects.